Metabolic Regulation of Myeloid-Derived Suppressor Cell Function in Cancer

被引:41
|
作者
Wang, Yufei [1 ]
Jia, Anna [1 ]
Bi, Yujing [2 ]
Wang, Yuexin [1 ]
Liu, Guangwei [1 ]
机构
[1] Beijing Normal Univ, Key Lab Cell Proliferat & Regulat Biol, Minist Educ, Inst Cell Biol,Coll Life Sci, Beijing 100875, Peoples R China
[2] Beijing Inst Microbiol & Epidemiol, State Key Lab Pathogen & Biosecur, Beijing 100071, Peoples R China
关键词
cancer; myeloid-derived suppressor cells; MDSCs; metabolism signaling pathway; immune cell differentiation; tumor immunotherapy; immunotherapy; cell differentiation; IMMUNE SUPPRESSION; IMMUNOSUPPRESSIVE ACTIVITY; LIPID-METABOLISM; TUMOR-GROWTH; L-ARGININE; T-CELLS; ADENOSINE; INHIBITION; DIFFERENTIATION; ACTIVATION;
D O I
10.3390/cells9041011
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Myeloid-derived suppressor cells (MDSCs) are a group of immunosuppressive cells that play crucial roles in promoting tumor growth and protecting tumors from immune recognition in tumor-bearing mice and cancer patients. Recently, it has been shown that the metabolic activity of MDSCs plays an important role in the regulation of their inhibitory function, especially in the processes of tumor occurrence and development. The MDSC metabolism, such as glycolysis, fatty acid oxidation and amino acid metabolism, is rewired in the tumor microenvironment (TME), which enhances the immunosuppressive activity, resulting in effector T cell apoptosis and suppressive cell proliferation. Herein, we summarized the recent progress in the metabolic reprogramming and immunosuppressive function of MDSCs during tumorigenesis.
引用
收藏
页数:20
相关论文
共 50 条
  • [41] Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients
    Filipazzi, Paola
    Huber, Veronica
    Rivoltini, Licia
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2012, 61 (02) : 255 - 263
  • [42] Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients
    Paola Filipazzi
    Veronica Huber
    Licia Rivoltini
    Cancer Immunology, Immunotherapy, 2012, 61 : 255 - 263
  • [43] Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma
    Raychaudhuri, Baisakhi
    Rayman, Patricia
    Ireland, Joanna
    Ko, Jennifer
    Rini, Brian
    Borden, Ernest C.
    Garcia, Jorge
    Vogelbaum, Michael A.
    Finke, James
    NEURO-ONCOLOGY, 2011, 13 (06) : 591 - 599
  • [44] The impact of TLR ligands on the function and phenotype of myeloid-derived suppressor cell subpopulations
    Noerenberg, Daniel
    Bauer, Helen
    Wedekind, Georg
    Bittner, Philipp
    Zoglmeier, Christine
    Bourquin, Carole
    INFLAMMATION RESEARCH, 2010, 59 : S91 - S91
  • [45] Metabolic Reprogramming of Myeloid-derived Suppressor Cells in the Tumor Microenvironment
    Liu, Liang
    Huo, Shuping
    Liu, Jianghui
    Li, Qiaomin
    Wang, Jing
    DISCOVERY MEDICINE, 2021, 31 (164) : 141 - 146
  • [46] Myeloid-derived suppressor cells
    Nagaraj, Srinivas
    Gabrilovich, Dmitry I.
    IMMUNE-MEDIATED DISEASES: FROM THEORY TO THERAPY, 2007, 601 : 213 - 223
  • [47] Myeloid-Derived Suppressor Cells
    Gabrilovich, Dmitry I.
    CANCER IMMUNOLOGY RESEARCH, 2017, 5 (01) : 3 - 8
  • [48] Myeloid-Derived Suppressor Cells
    Woodland, David L.
    VIRAL IMMUNOLOGY, 2017, 30 (02) : 81 - 81
  • [49] Targeting Myeloid-Derived Suppressor Cells in Ovarian Cancer
    Mabuchi, Seiji
    Sasano, Tomoyuki
    Komura, Naoko
    CELLS, 2021, 10 (02) : 1 - 12
  • [50] Targeting myeloid-derived suppressor cells for cancer therapy
    Hongchao Tang
    Hao Li
    Zhijun Sun
    Cancer Biology & Medicine , 2021, (04) : 992 - 1009